Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name file name title title
tabling member	label

Search

692149

	registered interest
	date	20/02/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Chronic Obstructive Pulmonary Disease
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, with respect to chronic obstructive pulmonary disease, what was the NHS's annual clinical negligence bill for the 2016–17 financial year and what it is projected to be for the 2017–18 financial year; whether any statistical correlations between negligence payments made by NHS Trusts and care quality indicators have been examined; and if so, what are those correlations.
	tabling member printed	Lord Freyberg
	uin	HL5443
	answer	answer is ministerial correction date of answer 23/02/2017 answer text <p>Information to answer these questions is not held in this format by either the Department or the NHS Litigation Authority (NHS LA). The NHS LA records information on clinical negligence claims against the National Health Service but it does not record specific information on claims relating to chronic obstructive pulmonary disease or cardiac rhythm management devices. It is therefore not possible to provide information on clinical negligence costs relating to these conditions or to provide information on any statistical correlations between negligence payments made by NHS trusts in relation to these conditions and care quality indicators.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL5446 question first answered 23/02/2017 14:50:35 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2593 label Biography information for Lord Freyberg

714921

	registered interest
	date	29/03/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	IVF
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, with reference to paragraphs 2.8, 2.9 and 3.17 of the minutes of 9 March 2017 of the Licence Committee of the Human Fertilisation and Embryology Authority, regarding the follow-up of children born following pronuclear transfer between embryos, who is responsible for the follow-up programme in NHS England; what health, genetic and epigenetic parameters are to be measured; what assessment they have made of the potential for long-term medical problems to only become evident after five years of age; whether they intend to conduct follow-ups beyond five years of age; and whether they will place in the Library of the House a copy of the full documented processes that are in place setting out how follow-ups will be carried out.
	tabling member printed	Lord Alton of Liverpool
	uin	HL6409
	answer	answer is ministerial correction date of answer 06/04/2017 answer text <p>The Human Fertilisation and Embryology Authority has advised that the guidance on the follow up of any children born following mitochondrial donation is set out in paragraph 33.33 in Guidance Note 33 of the Authority’s code of practice. This requires the centre to have a documented process setting out how children born from mitochondrial donation will be followed up, where the patients have consented to follow-up. These should include long-term medical follow-up of the children born. A copy of Guidance Note 33 is attached.</p><p> </p><p>NHS England has agreed funding of £8 million over five years for an evaluative commissioning programme of mitochondrial donation, working closely with the partner organisations such as the Wellcome Trust.</p> answering member printed Lord O'Shaughnessy question first answered 06/04/2017 10:57:08 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name CoP_June_2016_GN33.pdf title Guidance Note 33
	tabling member	738 label Biography information for Lord Alton of Liverpool

714754

	registered interest
	date	28/03/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	IVF
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, with reference to paragraph 2.8 of the minutes of 9 March 2017 of the Licence Committee of the Human Fertilisation and Embryology Authority (HFEA) regarding babies born following pronuclear transfer between embryos, what procedures are in place to (1) identify whether a child born following pronuclear transfer is born with (a) a mitochondrial disease, (b) a genetic or epigenetic abnormality, (c) a birth defect, or (d) some other adverse outcome, (2) notify the HFEA in cases of any such adverse outcome, and (3) identify any such adverse outcome and notify the HFEA where consent for follow-up has not been granted.
	tabling member printed	Lord Alton of Liverpool
	uin	HL6374
	answer	answer is ministerial correction date of answer 06/04/2017 answer text <p>The Human Fertilisation and Embryology Authority (HFEA) has advised that, as set out in Guidance Note 33 of the Authority’s code of practice, centres carrying out mitochondrial donation are required to have documented processes in place setting out how the health of children born from mitochondrial donation will be followed up. A copy of Guidance Note 33 is attached.</p><p> </p><p>If the centre becomes aware that any child born as a result of mitochondrial donation has a mitochondrial disease, birth defect, genetic abnormality or if there has been any other adverse outcome, the centre must report this to the HFEA in accordance with the adverse incidents requirements set out in Guidance Note 27 of the code of practice. A copy of Guidance Note 27 is attached.</p> answering member printed Lord O'Shaughnessy attachment 1 file name CoP_June_2016_GN33.pdf title Guidance Note 33 2 file name CoP_June_2016_GN27.pdf title Guidance Note 27 question first answered 06/04/2017 10:53:18 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	738 label Biography information for Lord Alton of Liverpool

714753

	registered interest
	date	28/03/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	IVF
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, with reference to paragraph 2.3 of the minutes of 9 March 2017 of the Licence Committee of the Human Fertilisation and Embryology Authority, which non-CE marked reagents will be used by Centre 0017 for the purposes of treatment involving pronuclear transfer between embryos to prevent transmission of serious mitochondrial disease; which laboratories will test the non-CE marked reagents for sterility and toxicity; and why non-CE marked reagents are being used.
	tabling member printed	Lord Alton of Liverpool
	uin	HL6373
	answer	answer is ministerial correction date of answer 05/04/2017 answer text <p>The Human Fertilisation and Embryology Authority has advised that it is a condition of a licence that CE marked medical devices must be used wherever possible. In the case of pronuclear transfer, there are no appropriate CE marked reagents, meaning that for treatment to take place, non-CE marked reagents must be used. In this case, the centre must adhere to paragraph 26.5 in Guidance Note 26 of the Authority’s code of practice, which states that if a centre modifies a CE marked product or uses a product “off label”, it must complete a risk assessment and validation to ensure the product is safe. A copy of the Guidance Note 26 is attached.</p> answering member printed Lord O'Shaughnessy question first answered 05/04/2017 14:18:48 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name Guidance_Note_26_-_Equipment_and_materials.pdf title Guidance Note 26
	tabling member	738 label Biography information for Lord Alton of Liverpool

671098

	registered interest
	date	10/01/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prescriptions
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, in the light of the widespread adoption of the Electronic Prescription Service by pharmacies, whether an audit has been undertaken to determine the impact on the cost of providing prescriptions; and if so, whether those costs rose or fell, and by how much.
	tabling member printed	Lord Bradshaw
	uin	HL4501
	answer	answer is ministerial correction date of answer 19/01/2017 answer text <p>The impact of the Electronic Prescription Service (EPS) has been extensively validated and continuously reviewed by NHS Digital, including for pharmacies and other dispensers. For example, provisional findings from an independent audit, which measure cost in time rather than a monetary value, have identified time savings per prescription dispensed. These findings have yet to be finalised and the final audit report is expected to be published in due course.</p><p> </p><p>Greater efficiencies, an improved audit trail and better customer service have also been found by NHS Digital and the independent audit, in respect of pharmacies using EPS.</p><p> </p> answering member printed Lord O'Shaughnessy question first answered 19/01/2017 17:55:49 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2483 label Biography information for Lord Bradshaw

693671

	registered interest
	date	23/02/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services: USA
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, in the light of the statement by the Secretary of State for Health in his speech to the Conservative Party Conference that "a country that works for everyone takes special care of the public service closest to everyone’s heart", what was the outcome of his recent visit to New York to discuss links and collaboration between the UK and US health sectors.
	tabling member printed	Lord Pendry
	uin	HL5575
	answer	answer is ministerial correction date of answer 27/02/2017 answer text <p>After the referendum vote to leave the European Union, the Secretary of State for Health committed to meeting the Chief Executives of the global top 10 pharmaceutical companies. As part of this, he visited New York to deliver assurance of the United Kingdom’s commitment to life sciences, research and innovation and to encourage United States investment in the UK life sciences sector.</p> answering member printed Lord O'Shaughnessy question first answered 27/02/2017 12:18:25 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	457 label Biography information for Lord Pendry

682659

	registered interest
	date	01/02/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, in the light of the proposals for a budget impact threshold being adopted by NHS England and the National Institute for Health and Care Excellence (NICE), how they intend to maintain guarantees regarding access within 90 days to NICE-approved medicines.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL5163
	answer	answer is ministerial correction date of answer 09/02/2017 answer text <p>Patients will continue to have a right in the National Health Service Constitution to drugs and treatments recommended in National Institute for Health and Care Excellence (NICE) technology appraisal guidance.</p><p> </p><p>The NHS Constitution right reflects the legal requirement on NHS commissioners to fund drugs and treatments recommended in NICE technology appraisal guidance, normally within three months of publication of final guidance from NICE. There is provision for NICE to extend the timescale for the introduction of the funding requirement where there are significant barriers to implementation within the standard three month timescale. The proposed budget impact threshold that has recently been subject to public consultation is intended in part to clarify the circumstances in which it is appropriate to extend the timescale for implementation of NICE’s technology appraisal recommendations.</p><p><strong> </strong></p> answering member printed Lord O'Shaughnessy question first answered 09/02/2017 17:51:46 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

712577

	registered interest
	date	20/03/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services: Learning Disability
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, in the light of the commitment made in <i>Transferring Care for People with Learning Disabilities - Next Steps</i>, published in January 2015, to establish a reconfiguration taskforce to support local leaders to reshape services in the north of England, what progress they have made in this regard.
	tabling member printed	Baroness McIntosh of Pickering
	uin	HL6172
	answer	answer is ministerial correction date of answer 30/03/2017 answer text <p>Since January 2015 significant progress has been made against this commitment in the North of England.</p><p> </p><p>Work was undertaken in in the summer of 2015 in designated ‘Fast Track’ areas, including in Lancashire, Greater Manchester and Cumbria and the North East region. Funding was provided to these areas to pilot the transformation of services in line with the new Building the Right Support (BRS) service model. Each Fast Track area focussed on the development of different services elements, but all demonstrated the local leadership and governance required to reshape services in these areas. To support this work, additional resources were provided for dedicated NHS regional teams in both the North and Midlands and East regions. Learning from this work in 2015 informed the broader roll-out of the BRS strategy from April 2016.</p><p> </p><p>Transforming Care Partnerships (TCPs) were rolled out from April 2016 nationally, with 10 being developed in the North. In the past 12 months, each TCP has developed a leadership and governance structure, set out a transformation plan, and begun developing services as part of a three year programme of delivery. At the regional level, a North Transforming Care Board is attended by all relevant TCP Senior Responsible Officers, with senior representation from all partnership bodies including NHS England, the Local Government Association, voluntary sector partners as well as people with lived experience. This Board is key for assuring and challenging the planning and delivery undertaken by TCPs. It also provides an opportunity for shared learning and development.</p> answering member printed Lord O'Shaughnessy question first answered 30/03/2017 15:18:32 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	384 label Biography information for Baroness McIntosh of Pickering

685923

	registered interest
	date	07/02/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Electronic Cigarettes
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, in the light of the UCL report <i>Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine Replacement Therapy Users: A Cross-sectional Study</i> which found that people who switch to vaping have 97.5 per cent lower levels of NNA in their system, whether they will encourage people to switch from smoking cigarettes to vaping.
	tabling member printed	Lord Blencathra
	uin	HL5326
	answer	answer is ministerial correction date of answer 16/02/2017 answer text <p>The Government has been and continues to be clear that vaping is substantially less harmful than continuing to smoke, and that the best thing a smoker can do for their heath is to stop smoking completely. This study supports the Government’s policy approach, demonstrating that to reduce exposure to harmful chemicals significantly, those smokers who chose to vape should substitute smoking with vaping entirely.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL5327 question first answered 16/02/2017 14:27:53 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	497 label Biography information for Lord Blencathra

706318

	registered interest
	date	28/02/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mental Health Services: Children and Young People
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, in the light of the <i>Lightning Review</i> by the Children’s Commissioner published in May 2016 stating that "79% of Child and Adolescent Mental Health Services stated that they imposed restrictions and thresholds on children and young people accessing their services", what are those (1) thresholds, and (2) restrictions.
	tabling member printed	Baroness Fall
	uin	HL5697
	answer	answer is ministerial correction date of answer 13/03/2017 answer text <p>The report, <em>Lightning Review: Access to Child and Adolescent Mental Health Services</em>, was published independently by the Children’s Commissioner published in May 2016.</p><p> </p><p>In the report, the Children’s Commissioner mentioned what they described as thresholds and restrictions to services. In the report these included the age of patients; the conditions that patients present with; the severity of conditions; and the severity of symptoms.</p> answering member printed Lord O'Shaughnessy question first answered 13/03/2017 12:20:20 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4561 label Biography information for Baroness Fall